Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q4 FY21 results · Jan–Mar 2021
Astec LifeSciences reported revenue from operations of ₹171.92 crore (down 4.8% from Q4 FY20) and net profit of ₹23.97 crore (down 23.1% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 171.92 | 180.57 | −4.8% | 116.01 | +48.2% |
| Other income | 1.55 | 5.24 | −70.5% | 3.27 | −52.7% |
| Total income | 173.47 | 185.81 | −6.6% | 119.28 | +45.4% |
| Profit before tax | 32.18 | 39.63 | −18.8% | 11.28 | +185.4% |
| Net profit for the period | 23.97 | 31.18 | −23.1% | 7.06 | +239.3% |
| Attributable to shareholders of the company | 23.96 | 31.18 | −23.1% | 7.06 | +239.5% |
| EPS, basic (₹) | 12.24 | 15.94 | −23.2% | 3.61 | +239.1% |
| Net margin (%) | 13.9 | 17.3 | 6.1 |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 171.92 | 180.18 | −4.6% | 116.01 | +48.2% |
| Other income | 1.55 | 5.24 | −70.5% | 3.27 | −52.7% |
| Total income | 173.47 | 185.43 | −6.4% | 119.28 | +45.4% |
| Profit before tax | 32.15 | 39.61 | −18.8% | 11.25 | +185.6% |
| Net profit for the period | 23.94 | 31.17 | −23.2% | 7.05 | +239.7% |
| EPS, basic (₹) | 12.23 | 15.94 | −23.3% | 3.60 | +239.7% |
| Net margin (%) | 13.9 | 17.3 | 6.1 |
Consolidated
- Filed with BSE
- 03 May 2021, 13:51 IST
- Board meeting
- 30 Apr 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 03 May 2021, 13:51 IST
- Board meeting
- 30 Apr 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE